| abstract |
Putative Adrenomedullin Receptor polypeptides and polynucleotides and methods fornproducing such polypeptides by recombinant techniques are disclosed. Also disclosed arenmethods for utilizing Putative Adrenomedullin Receptor polypeptides and polynucleotides in thendesign of protocols for the treatment of infections such as bacterial, fungal, protozoan and viralninfections, particularly infections caused by HIV-1 or HIV-2; pain; cancers; diabetes, obesity;nanorexia; bulimia; asthma; Parkinson's disease; acute heart failure; hypotension; hypertension;nurinary retention; osteoporosis; angina pectoris; myocardial infarction; ulcers; asthma; allergies;nbenign prostatic hypertrophy; psychotic and neurological disorders, including anxiety,nschizophrenia, manic depression, delirium, dementia, severe mental retardation and dyskinesias,nsuch as Huntington's disease or Gilles dela Tourett's syndrome; and pre-eclampsia, among othersnand diagnostic assays for such conditions. |